The management of coronavirus infections with particular reference to SARS. (Q34012358)

30 July 2017

2 references

22 October 2022

The management of coronavirus infections with particular reference to SARS. (English)

1 reference

30 July 2017

0 references

1 reference

1 reference

2

Kwok-Yung Yuen

1 reference

30 July 2017

1

Samson S Y Wong

1 reference

PubMed ID

18565970

30 July 2017

language of work or name

English

0 references

publication date

18 June 2008

1 reference

PubMed ID

18565970

30 July 2017

1 September 2008

1 reference

22 October 2022

5

1 reference

Journal of Antimicrobial Chemotherapy

inferred from page(s)

published in

2 references

30 July 2017

22 October 2022

62

1 reference

30 July 2017

3

1 reference

30 July 2017

437-441

1 reference

Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection

30 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Coronaviruses and their therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Antiviral strategies against human coronaviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Potential antivirals and antiviral strategies against SARS coronavirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

SARS: systematic review of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Viral loads in clinical specimens and SARS manifestations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Fatal aspergillosis in a patient with SARS who was treated with corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Use of convalescent plasma therapy in SARS patients in Hong Kong.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Severe acute respiratory syndrome coronavirus 3C-like protease-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Management of severe acute respiratory syndrome: the Hong Kong University experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Household transmission of SARS, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Secondary household transmission of SARS, Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Antiviral effects of saikosaponins on human coronavirus 229E in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Inhibition of human coronavirus NL63 infection at early stages of the replication cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKN243

Lung pathology of fatal severe acute respiratory syndrome.

21 January 2018

1 reference

12 December 2020

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

1 reference

12 December 2020

Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine

1 reference

12 December 2020

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

1 reference

12 December 2020

Indomethacin has a potent antiviral activity against SARS coronavirus

1 reference

12 December 2020

Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features

1 reference

12 December 2020

Prevention of experimental coronavirus colds with intranasal alpha-2b interferon

1 reference

12 December 2020

A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection

1 reference

12 December 2020

Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

1 reference

12 December 2020

Probable secondary infections in households of SARS patients in Hong Kong

1 reference

12 December 2020

Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome

1 reference

12 December 2020

Development of antiviral therapy for severe acute respiratory syndrome.

1 reference

12 December 2020

Coronavirus as a possible cause of severe acute respiratory syndrome

1 reference

12 December 2020

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

1 reference

12 December 2020

Identifiers

DOI

10.1093/JAC/DKN243

1 reference

30 July 2017

0 references

1 reference

PubMed ID

18565970